-
100% LIFE, Ukraine
100% Life is the largest patient-led organization in Ukraine. Operating in 25 regions in Ukraine, the organization works to provide...
-
100% LIFE – 2018 Annual Report
Our partner, 100% LIFE, is the largest patient organization in Ukraine. 100% LIFE employs a range of strategies in order...
-
In times of peace and in times of war: 100% LIFE outstanding work in Ukraine
After two years of the worst pandemic in recent history, 2022 marked an extra tragic event in the history of...
-
Ukraine: 100% LIFE opposes patent on TB drug for children
Our campaign partner in Ukraine, 100% LIFE, has submitted the first patent opposition on bedaquiline in the Eastern Europe and Central...
-
ITPC Global Hosts Summit, Marking 30 years of Global Injustice
Organized by ITPC Global and the Make Medicines Affordable consortium, the summit brought together over 100 activists, policymakers, and researchers...
-
A look into the findings of the Market Intelligence Study for Uganda
In full recognition of the gloom that hovers around the withdrawal of funds, allow me shed a little light to...
-
An Earsplitting Silence: Pharma Makes Billions, Says Nothing About the Current Global Funding Crisis for HIV, Tuberculosis and Other Life-Threatening Illnesses
“It is shocking that the crisis facing the global HIV community has been met with such a resounding silence from...
-
‘A Matter of Life and Death’: Civil Society Groups Fight for Affordable DR-TB Treatment
“As the patent holder, Otsuka has prevented access to improved TB treatment due to its exorbitant prices. On World TB...
-
TNP+ is Successfully Opposing Big Pharma’s Hepatitis C Drug Monopoly
This win comes after years of campaigning by the AIDS Access Foundation (AAF) and the Thai Network of People Living...
-
Lenacapavir Patent Faces Opposition at the Eurasian Patent Office
“If Gilead Science’s patent application regarding Lenacapavir is granted, the patent will represent another significant barrier to the affordable access...
-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...
-
Ukrainian Patient Rights Group Opposes a Patent Applications on a Life-Saving HIV Drug
Rilpivirine, commonly known as RPV, is available in multiple formulations, including a daily oral medication, and in fixed-dose combination tablets,...
